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Abstract
Background: The response of mammalian glial cells to chronic degeneration and trauma is hypothesized to be
incompatible with support of neuronal function in the central nervous system (CNS) and retina. To test this
hypothesis, we developed an inducible model of proliferative reactive gliosis in the absence of degenerative stimuli
by genetically inactivating the cyclin-dependent kinase inhibitor p27
Kip1 (p27 or Cdkn1b) in the adult mouse and
determined the outcome on retinal structure and function.
Results: p27-deficient Müller glia reentered the cell cycle, underwent aberrant migration, and enhanced their
expression of intermediate filament proteins, all of which are characteristics of Müller glia in a reactive state.
Surprisingly, neuroglial interactions, retinal electrophysiology, and visual acuity were normal.
Conclusion: The benign outcome of proliferative reactive Müller gliosis suggests that reactive glia display context-
dependent, graded and dynamic phenotypes and that reactivity in itself is not necessarily detrimental to neuronal
function.
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Background
In response to neural pathologies, glia display reactive
properties associated with wound healing including cel-
lular hypertrophy, proliferation, migration and cytokine
release [1-4]. In mammalian CNS and retina, reactive
glia contribute to neural tissue repair [5-10] but also to
neural dysfunction, scar formation, abberant neural
rewiring, and vascular remodeling [1-3,11,12], ultimately
exacerbating neuronal degenerations [11,13]. Defining
the components of reactive gliosis that are detrimental
to neuronal survival and tissue integrity is an important
goal but difficult to achieve. Animal models of reactive
gliosis also induce neuronal cell death, microglial reac-
tivity, inflammatory responses or tissue damage
[1,3,4,14]. An alternate approach to explore glial reactiv-
ity and neuronal metabolism, physiology and function is
to develop genetically inducible models of reactivity in
the absence of gross degenerative cues.
Two hallmarks of reactive glia are proliferation and
enhanced intermediate filament expression. Both are
associated with opposing properties: neuroprotection
and degeneration. Experimental models and gene inacti-
vation studies implicate upregulation of intermediate
filament expression in the formation of hypertrophic
glial processes. Glial hypertrophy helps maintain the
structural integrity of the CNS by filling the space
where neurons die and by restoring damaged protective
barriers [9,15,16]. However, intermediate filaments are
abundant in glial scars which are known to impede axo-
nal regeneration [17,18]. Chronic upregulation of inter-
mediate filament expression is also correlated with glial
metabolic dysfunction and altered neuronal electrophy-
siology [12,19-21]. The role of glial proliferation is simi-
larly perplexing. Genetic ablation of proliferating glia
worsens neurodegeneration [5,6] while pharmacological
inhibition of glial proliferation enhances neuronal survi-
val and function [14,22]. Given these complexities, more
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and progressive neurodegeneration are needed.
The cyclin-dependent kinase inhibitor p27 is one such
l i n k .I ti se x p r e s s e di nm a n ya d u l tg l i a lp o p u l a t i o n s
including Schwann cells, cortical astrocytes, spinal cord
astrocytes, oligodendrocytes, and retinal Müller glia
[23-27]. In germline p27-deficient mice (p27
-/-), adult
glia can display hallmarks of reactive gliosis [24-26,28].
In the wild-type retina, quiescent Müller glia normally
do not express the intermediate filament glial fibrillary
acidic protein (GFAP), but Müller glia in p27
-/- mice
express high levels of GFAP and in some instances
migrate into the subretinal space [24,26]. This behavior
is enhanced by the combinatorial inactivation of p27
and the cyclin-dependent kinase inhibitor p19
Ink4d [29].
Müller glial reactivity and abnormal retinal electrophy-
siology in p27
-/- mice may partly arise from develop-
mental dysregulation as p27 is critical for neural
development and glial differentiation [24,26,30-33]. Even
so, CNS and retinal trauma models support a role for
p27 in maintaining mature glial cells in a quiescent, sup-
portive state. After acute trauma, cortical astrocytes,
spinal cord astrocytes and retinal Müller glia downregu-
late p27, upregulate GFAP and re-enter the cell cycle
[14,25,27,34]. Thus p27 appears to be a negative regula-
tor of two classic indices of reactive glia: GFAP upregu-
lation and proliferation. This implies that selective
inactivation of p27 could trigger neural remodeling and
reprogramming defects in an otherwise normal milieu.
To modulate discrete reactivity indices in the absence
of other degenerative stimuli, we induced intermediate
filament GFAP upregulation, migration, and prolifera-
tion in adult Müller glia by inactivating p27 using a
tamoxifen-regulated, Cre-loxP system [35,36]. This
approach bypassed the developmental requirement for
p27 [24,26] as well as the complexities and broad effects
of experimentally induced degeneration [1,3,4,14]. To
address the significance of enhanced discrete reactivity
on neuronal survival and function, we surveyed metabo-
lism, retinal electrophysiology, and visual acuity. Con-
trary to our expectations, proliferative and GFAP-
expressing Müller glia did not significantly impair retinal
metabolism, electrophysiology, or visual function. Thus,
our genetic model and the p27 pathway offer a new
platform to explore how environmental factors involved
in neuronal cell stress, microglial activation, inflamma-
tory responses, or blood barrier damage contribute to
the transition of resident glia from a supportive to detri-
mental state.
Results
Inducible model of p27 deficiency in adult mice
We conditionally targeted the p27 coding region in
adult mice harboring LoxP sites at the p27 locus (p27
L
+), and expressing a tamoxifen-regulated Cre recombi-
nase under the control of the chimeric chicken beta-
actin promoter, CAGG::CreER™ (Figure 1A and 1B)
[35,36]. Since high levels of tamoxifen can be toxic to
retinal cells [37], expressing CreER™ with a strong pro-
moter facilitated a tamoxifen dose that did not cause
neuronal cell death or reactive gliosis (50 μg tamoxifen/
gbw, see methods; Figure 1C and analyses below).
Importantly, this dose greatly reduced p27 expression in
targeted mice (p27
L-; Figure 1C-F). Inactivation effi-
ciency was higher in the central retina than in the per-
ipheral retina (90.0 ± 7.3 and 68.5 ± 10.7%; Figure 1F
and Additional file 1). These results are consistent with
previous recombination studies in adult retina and
might reflect variability in CreER™ expression or
tamoxifen accesibility [36,38]. Müller glia failing to
undergo p27 inactivation allowed us to discriminate
between cell autonomous and non-cell autonomous
effects of p27 inactivation. While genetic deletion of p27
can also occur in neurons expressing CreER™, this was
likely inconsequential as mature retinal neurons do not
express p27 [24,26]. Thus, our model of p27 inactivation
displayed optimal experimental conditions to define the
role of p27 in Müller glial reactivity.
p27-deficient Müller glia upregulate intermediate
filaments
Since upregulation of the intermediate filament GFAP is
a hallmark of glial reactivity, we examined GFAP immu-
noreactivity in retinas from p27
L-/L- mice and tamoxifen
control mice (Figure 1C). Tamoxifen control retinas dis-
played two distinct patterns of GFAP expression. In the
central retina, astrocytes located at the ganglion cell
layer expressed GFAP (Figure 2A). At the far periphery,
radial processes expressed GFAP that colocalized with
Müller glial markers (Additional file 1). The patterns of
GFAP expression in tamoxifen control retinas were con-
sistent with those previously observed in wild-type reti-
nas [39,40]. After p27 inactivation, western blots
revealed enhanced expression of a 50-kDa GFAP band
and of a lower molecular weight band (Figure 1C)
which correlated with increased GFAP immunoreactivity
in Müller glia both in the central and peripheral retina
(Figure 2A and 2B; Additional file 1). Temporal and spa-
tial analyses of GFAP-immunoreactivity revealed three
distinct patterns of expression (Figure 2C). Seven days
after the start of the p27 inactivation protocol, only a
small percentage of Müller glia (5.5 ± 1.5%) displayed
GFAP immunoreactivity restricted primarily to the end
feet at the ganglion cell layer. Three to six weeks after
inactivation, almost all Müller glia (91.9 ± 7.3%) dis-
played GFAP immunoreactivity throughout their cell
bodies. Nearly four months after inactivation, the num-
ber of GFAP
+ Müller glia (34.4 ± 7.9%) and the extent
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decreased. We also observed that a small percentage of
p27
+ Müller glia expressed GFAP (Additional file 1,
arrows), which suggests that p27 inactivation might
influence cells through a non-autonomous mechanism.
However, the vast majority of GFAP expression was
observed in p27-deficient Müller glia (Figure 2B). We
also found upregulation of the intermediate filaments
vimentin and nestin in p27-deficient Müller glia (Addi-
tional file 1).
p27-deficient Müller glia reenter the cell cycle
Müller glia do not proliferate under normal conditions
in part due to the presence of cell cycle inhibitors
such as p27 [24,25]. After conditional p27 inactivation,
however, cells reentered the cell cycle as indicated by
the upregulation of proliferative markers PCNA,
pHH3, and MCM6 (Figure 2D and Additional file 2) as
well as bromodeoxyuridine (BrdU) labeling (Figure 2E
and 2F). BrdU injections followed by a six week chase
revealed that BrdU colocalized with Müller glial
markers SOX9 and glutamine synthetase (GLUL, Fig-
ure 2F) and not with photoreceptor or bipolar markers
(Recoverin, OTX2, PKC-alpha). While the number of
SOX9
+-GLUL
+ nuclei increased by 15.8% (p <0.00003)
the number of GLUL
+ stalks at the inner plexus layer
decreased by 6.1% (p < 0.006) (Figure 2D). Increased
GLUL
+ soma density with decreased stalk density was
confirmed with ultrathin radial and oblique sections
suggesting that proliferative Müller glia can retract
their stalks before dividing and neither they or their
daughters regrow stalks after dividing (Additional file
3). These data indicate that p27 inactivation in Müller
glia was sufficient to induce cell cycle entry with a low
level of proliferation.
SOX9 and GLUL immunoreactivity also revealed that
p27-deficient Müller glia displaced their nuclei toward
the photoreceptor layer (Figure 2F and Additional file
3). The displacement of Müller glial nuclei occured one
week after the start of p27 inactivation and the ectopic
location was irreversible. It is unclear whether the
nuclear displacement reflects migration of Müller glia or
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Figure 1 Inducible model of p27
Kip1 inactivation in adult mice. (A) The p27 coding region was conditionally targeted by generating mice
harboring LoxP sites at the p27 locus (p27
L+) and expressing a tamoxifen-regulated Cre recombinase under the control of the chimeric chicken
beta-actin promoter, CAGG::CreER™. (B) Experimental design: Tamoxifen was administered by single daily intraperitoneal injections (i.p.) for 5
consecutive days in 2 month-old mice. For proliferation analysis, BrdU was injected once daily for three consecutive days starting 8 days after
the first tamoxifen injection. All timepoints were calibrated to the start of tamoxifen exposure. (C) Western blots for p27 and the marker of glial
reactivity GFAP. Each lane contains 15 μg of protein from individual retinas. The blot was cut at ~35 kDa: portions with the lower and higher
molecular weight bands were stained for p27 and GFAP, respectively. (D and E) Immunostaining against p27 and the Müller glial marker
Glutamine Synthetase (GLUL). Micrographs of control (p27
L-/L+) and experimental animals (p27
L-/L-) six weeks after the start of tamoxifen
injections. Asterisks indicate blood vessels. Arrowheads denote Müller glia that failed to undergo p27 inactivation. (F) Inactivation efficiency was
measured by comparing the number of p27
+ cells colocalizing with the glial nuclear marker SOX9. Data are expressed as the mean ± SD.
Abbreviations: ONL, outer nuclear layer; INL, inner nuclear layer; RGC, retinal ganglion cell layer; p27, cyclin-dependent kinase inhibitor CDKN1B;
GFAP, glial fibrillary acidic protein; GLUL, glutamine synthetase; SOX9, SRY-box containing gene 9; and DAPI, 4’, 6-diamidino-2-phenylindole.
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ing migratory-like behavior is the presence of focal and
limited extension of GFAP
+ Müller glial endfeet into the
photoreceptor segments (Additional file 4, arrows); but
unlike p27
-/- retina [24,26], p27
L-/L- retina displayed con-
tinuous outer limiting membrane as seen by the Müller
glia microvilli marker CD44 (Additional file 4). In sum,
induced p27 deficiency results in adult Müller glia
adopting classic indices of proliferative reactive gliosis:
intermediate filament upregulation, cell cycle entry, and
migratory-like behavior.
Reactive p27
L-/L- Müller glia provide homeostatic
metabolic support
The ability of reactive glia to maintain metabolic sup-
port and neuronal function is unclear as reactive glia
often downregulate metabolic enzymes during neuronal
degenerations [4,11,21,41]. We visualized and quantified
the metabolic support that glia offer both excitatory and
inhibitory neurons–glutamate and g-Aminobutyric acid
(GABA) uptake and their ultimate recycling into gluta-
mine–using computational molecular phenotyping
(CMP, Figure 3A). CMP measures metabolite concentra-
tion in N-dimensional space at the single cell level
[12,21,42]. Molecular mapping on 200 nm sections with
silver intensification revealed the spatial distributions of
glutamate, glutamine, and glutamine synthetase during
the peak of GFAP upregulation (6 weeks post-inactiva-
tion, Figure 3B-E). The ability of p27-deficient Müller
glia to metabolize glutamate is so efficient that their
somas and their endfeet displayed low levels of gluta-
mate (Figure 3C, arrow heads and arrows). Metabolic
maps representing taurine, glutamate and glutamine sig-
nals into red-green-blue channels revealed the compart-
mentalization of glutamate in excitatory neurons such as
photoreceptors, bipolar cells and ganglion cells (Figure
3F and 3G, blue to purple hues). In these metabolic
maps, the highly conserved taurine-glutamine signature
of Müller glia (the yellow background) [12,21,42] is
maintained in p27
L-/L- retina. Metabolite pixel values
extracted using either the glutamine synthetase signal as
a mask or formal multi-channel clustering [42] revealed
that p27-deficient Müller glia maintained statistically
inseparable levels of glutamate and glutamine compared
to tamoxifen control retinas (Figure 3H). Additional
markers of glial function including osmoregulation
(taurine), redox function (glutathione), retinoid binding
(cellular retinaldehyde-binding protein, CRALBP), and
GABA recyling (GABA) were also unchanged (Figure
3H and Additional file 3E). Metabolite concentrations
and distributions for photoreceptors and retinal pigmen-
ted epithelium were comparable in tamoxifen control
and p27
L-/L- retinas. The p27-deficiency did not alter the
levels of metabolites and enzymes important for retinal
homeostasis and neuronal function.
Normal electrophysiology in retinas with reactive p27
L-/L-
Müller glia
Several studies suggested that reactive gliosis alters neu-
ronal responsivity well before any indication of neuronal
cell death [12,19-21]. We therefore examined retinal
function by electroretinography (ERG) during the peak
of GFAP upregulation and during chronic GFAP expres-
sion (6 and 16 weeks post-inactivation). During these
time periods the Müller glia nuclei migrated from their
normal position (mid-inner retinal layers) toward the
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Figure 2 Inducible p27 inactivation results in enhanced
intermediate filament GFAP expression, glial cell-cycle entry,
and glial nuclear migration. (A and B) Immunostaining for p27
and the marker of glial reactivity GFAP. Micrographs of tamoxifen
control (p27
L-/L+) and experimental (p27
L-/L-) retinas six weeks after
the start of tamoxifen injections. Asterisks indicate blood vessels. (C
and D) Quantitation of Müller glia becoming reactive (GFAP
+) and
entering cell cycle (PCNA
+) as well as the total number of Müller
glial nuclei (SOX9
+) and stalks (GLUL
+). Curves were generated using
the Smooth marked scatter option in Excel™. (E-F)
Bromodeoxyuridine (BrdU) injections followed by a six week chase
to reveal the fate of dividing cells. (E-F insets) Higher magnification
showing colocalization with glial marker GLUL. Data are expressed
as the mean ± SD. Abbreviations: PCNA, Proliferating cell nuclear
antigen.
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Page 4 of 11photoreceptor layer (Figure 2F and 3G). ERGs of tamox-
i f e nc o n t r o lm i c ew e r ee s s e n t i a l l yi d e n t i c a lt ot h o s eo f
adult wild-type mice. The p27
L-/L- a- and b-waves,
reflecting the functional integrity of photoreceptor and
bipolar cell signaling [43], were also normal under sco-
topic (rod-system) and photopic (cone system) condi-
tions (Figure 4A and 4B). The small increase in p27
L-/L-
b-wave amplitude and time-to-peak (Figure 4C and 4D)
might be caused by decreased net potassium channel
conductance in Müller glia [44,45]. However, the distri-
bution and immunoreactivity level of the glial potassium
channel Kir4.1 appeared normal in the p27
L-/L- retina
(Additional file 4C and 4D), suggesting the possibility of
increased impedence in Müller glia. Unlike the p27
-/-
retina [32,33], p27
L-/L- retina did not exhibit pathologies
characteristic of retinal dysfunctions such as reduced,
delayed, truncated, or inverted ERG signals [46].
Normal visual acuity and function in mice with reactive
p27
L-/L- Müller glia
We next tested photopic visual acuity using the opto-
motor response that evaluates the impact not only of
Müller glial reactivity but also of reactive glia along the
accessory optic system (Figure 5A), such as oligodendro-
cytes in the optic nerve, which normally express p27
(Additional file 4). Spatial frequency thresholds that eli-
cited an optomotor response were not statistically differ-
ent between tamoxifen control and experimental
animals during the peaks of Müller glial proliferation
and GFAP upregulation, or during chronic GFAP
expression (1.5, 6 and 16 weeks post-inactivation respec-
tively; Figure 5B). The spatial frequency threshold of the
optomotor response in tamoxifen control and experi-
mental animals (0.418 ± 0.027 cycles per degree) was
comparable to previously published values in mice [47].
Discussion
p27 is a negative regulator of proliferative Müller glial
reactivity
The hypothesis that p27 is a key modulator of glial plas-
ticity is supported by our finding that inducing p27-defi-
ciency is sufficient to promote proliferative Müller
reactive gliosis in adult retina [24-27,34]. As a cell cycle
inhibitor, p27 modulates glial proliferation and conse-
quently p27 can modulate the potential of glial cells to
regenerate neural tissue and to form scars [48]. In
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Figure 3 Reactive p27
L-/L- Müller glia maintain neuronal metabolic support. (A) Schematic of neuron-glia metabolic interaction via the
glutamate-glutamine cycle. (B-E) Differential metabolite content of cells in p27
L-/L- retina visualized and quantified using computational molecular
phenotyping (CMP). Plasticized tissue was serially sectioned at 200 nm, probed with specific anti-hapten IgGs, and visualized with silver-
intensification of 1.4 nm gold granules coupled to species-specific secondary IgGs. Each metabolic map was captured as a high-resolution,
monochrome image. (F-G) Metabolic mapping of tamoxifen control and experimental retina at the peak of GFAP expression (6 weeks after
tamoxifen injections). Red-green-blue channels represents taurine-glutamate-glutamine mapping highlighted with GLUL as an alpha-channel.
RGB images with alpha channels were prepared with Adobe Photoshop CS3. The yellow background is the distinctive taurine-glutamine
signature of Müller glia. The pink and red compartments in the photoreceptor outer segments (OS) and inner segments (IS) contain distinct
taurine-glutamate-glutamine mixtures. While various blue-to-azure cells in the interneuron layer (INL) and ganglion cell layer (GCL) are neurons
with distinctive glutamate-glutamine mixtures. (H) Metabolite pixel value in Müller glia was extracted using the GLUL signal. Data are expressed
as the mean ± SD. There was no statistically significant difference between tamoxifen control animals (n = 3) and experimental p27
L-/L- animals
(n = 3). Asterisks, arrows and arrowheads indicate blood vessels, endfeet and somas, respectively. Additional abbreviations: CRALBP, cellular
retinaldehyde-binding protein; GSH, glutathione.
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re-enter the mitotic cycle because of persistent p27
expression [48]. In contrast, Müller glia and astrocytes
adjacent to traumatic injuries downregulate p27 result-
ing in glial proliferation that contributes to scar
formation [34]. The absence of neurogenesis and scar
formation after our conditional p27 inactivation suggests
that while decreased p27 activity modulates glial prolif-
eration, transitioning to a neurogenic state or scar form-
ing phenotype must be determined by additional
signaling mechanisms. Indeed several groups found that
addition of neurogenic factors are required to guide pro-
liferating glia into a neurogenic state [24,25,48,49]. Our
conditional p27 inactivation also yielded nonproliferative
phenotypes including Müller glial nuclear migration,
cytoplasmic process extension, and increased intermedi-
ate filament content. These phenotypes are consistent
with data suggesting that the impact of p27 activity
extends beyond cell cycle regulation, possibly by modu-
lating transcription, cell fate, cell migration, or cytoske-
letal dynamics [30,31]. The issue of whether the
nonproliferative changes are the direct result of p27
deficiency or a secondary response to cell cycle reentry
will be addressed in future studies; however, it is clear
that p27 levels have broad effects on the outcome of
glial reactivity even in the absence of degenerative cues.
Consequently the p27 pathway represents a prime target
to facilitate glial-based regeneration and to modulate
glial scar formation.
Reactive gliosis displays context-dependent, graded and
dynamic phenotypes
Our genetic model of proliferative reactive gliosis is one
of several studies using gene targeting approaches to
define the role of specific pathways in reactive gliosis
(reviewed in [16,50,51]). The general theme from genetic
dissection studies is that reactive gliosis is a multifaceted
event whose diverse molecular, morphological and func-
tional changes are modulated by distinct signaling
mechanisms. Conditional inactivation of the signal
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Figure 4 Normal electrophysiology in retinas with reactive
p27
L-/L- Müller glia. Electroretinographic analysis was performed in
experimental p27
L-/L- and control mice during the peak of GFAP
upregulation and during chronic GFAP expression (6 and 16 weeks
post-inactivation). During these time periods the Müller glia nuclei
migrated from their normal position (mid-inner retinal layers)
toward the photoreceptor layer. Four to five mice were analyzed for
each condition. (A and B) Representative scotopic and photopic
electroretinogram (ERG) responses evoked by 10 decibel (dB) light
flashes were recorded after dark adaptation and light adaptation,
respectively. The fast components of the a- and b-waves reflect the
functional integrity of photoreceptor and bipolar cell signaling,
respectively. The slow components of the b-wave reflect Müller glial
conductance. (C and D) Wave amplitudes were averaged from 4-5
mice per condition and shown as function of stimulating light
intensity. Data are expressed as the mean ± SD.
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Figure 5 Normal visual acuity in p27
L-/L- mice using the optomotor response. (A) Known visual pathways interrogated by the optomotor
response test. (B) Optomotor tracking response to moving gratings was measured using a virtual optomotor system. Spatial frequency
thresholds that elicited an optomotor response between tamoxifen control and experimental animals during the peaks of Müller glial
proliferation and GFAP upregulation, and during chronic GFAP expression (1.5, 6 and 16 weeks post-inactivation, respectively). A sine wave
grating was drawn on a virtual cylinder projected on monitors and the cylinder was rotated to test each. The value for each animal represents
the average of both eyes. Data are expressed as the mean ± SD.
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Page 6 of 11transducer and activator of transcription 3 (Stat3)
decreases reactive astrocyte migration after traumatic
spinal cord injury [52]. Conditional inactivation of the
suppressor of cytokine signaling 3 (Socs3) enhances
reactive astrocyte migration [52]. In contrast our induci-
ble inactivation of p27 resulted in Müller glial cell cycle
entry and nuclear migration followed by intermediate
filament upregulation (Figure 6A), but did not result in
additional reactive gliosis components including hyper-
trophy, scar formation, edema, and loss of homeostatic
and metabolic enzymes (Figure 6B). Diversity in the glial
response to stress is widely documented by transcrip-
tome-wide studies. While there is a subset of gene
expression changes shared across models and CNS tis-
sues (for example, Gfap and Fos), there are context
dependent expression changes suggesting diversity and
complexity in the gliotic response [14,53,54]. Gene
expression data also suggest that the process of reactiv-
ity is dynamic with temporal changes clustering into at
least three categories: immediate, delayed and chronic
[14,53]. Thus, gene targeting and expression studies
argue that reactive gliosis is context-dependent, graded
and dynamic. As genetic targeting studies continue to
dissect individual components of reactive gliosis, a better
understanding of the functional significance of each
component and its role in specific conditions will
emerge.
Transient GFAP expression in Müller glia is compatible
with neuronal metabolism and function
Upregulation of the intermediate filament GFAP is argu-
ably the most extensively described hallmark of reactive
glia, yet it remains unclear whether this property is ben-
eficial or detrimental to neuronal function and survival.
The negative view regarding GFAP elevation stems from
the correlation between decreased metabolic support
and neuronal dysfunction with increased GFAP expres-
sion in the retina and brain [11,13,19,20,41]. For exam-
ple, retinal detachment upregulates GFAP expression
and concomitantly results in loss of GLUL expression
and extensive derangement of glial and neuronal meta-
bolite profiles [42]. Genetic targeting of intermediate
filament expression levels (inactivation or overexpres-
sion) [16,50] and our inducible model of reactive gliosis
reveal a complex role for intermediate filaments on the
physiology and pathology of glial cells. While mice lack-
ing intermediate filaments show no developmental or
motor functional deficits, they display compromised
blood-brain barrier, enhanced hippocampal long-term
potentiation, decreased cerebellar long-term depression,
white matter pathologies and demyelination [8,9,55,56].
In disease models, the absence of intermediate filaments
exacerbates traumatic and toxic injury, autoimmune
response, stroke, and scrapie prion infection by reducing
glial hypertrophy and scarring, and compromising the
ability of glial cells to osmoregulate, transport glutamate,
and repair the blood-brain barrier [7-10,56]. Positive
outcomes of reducing glial hypertrophy and scarring in
mice lacking intermediate filaments include enhanced
adult neurogenesis, axon regeneration, and neural graft
survival and integration [17,57,17,25]. However, the
extent to which increased regeneration potential
improves functional recovery in intermediate filament
deficient mice is controversial [9,10,17]. These findings
have raised the question that intermediate filament
upregulation plays a beneficial role in the acute stage,
but prolonged upregulation interferes with neuronal sur-
vival and regeneration [56]. Supporting this view is the
finding that mice transgenic for human GFAP accumu-
late high levels of GFAP leading to glial hypertrophy,
intracytoplasmic aggregates, stress response, oxidative
stress, microglial activation and neuronal dysfunction
[58,59]. In contrast, transient GFAP upregulation in
p27
L-/L- Müller glia was compatible with glial function
(osmoregulation, transmitter recyling, radical and
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Figure 6 Summary and model. (A) Comparison of retinal glial and
neuronal responses to p27 inactivation. Data values were
standardized for cross comparison. (B) Model of p27 inactivation
effect on glia and neuronal function. Conditional p27 deficiency
results in cell cycle entry and soma displacement, as well as in
enhanced intermediate filament expression (e.g., GFAP and VIM).
Surprisingly, these reactive changes are compatible with
homeostatic neuronal metabolism, electrophysiology and function.
The benign impact of inducible proliferative reactive gliosis in p27
L-/
L- mice raise the hypothesis that the transition from supportive to
deleterious is determined by external factors signaled from either
neuronal cell stress, microglial reactivity, inflammatory response,
blood barrier damage, or neuronal cell death.
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function. Taken together, data from mice with null,
transgenic, and transient GFAP expression suggest that
intermediate filament upregulation facilates the
cytoarchitectural remodeling necessary for glial cells to
protect the integrity of the tissue, limit the lesion site
and modulate basic neuroprotective function of glial
cells; but prolonged and robust intermediate filament
expression can lead to glial dysfunction.
Proliferative Müller reactive gliosis is insufficient to
induce glial dysfunction, scar formation or neurogenesis
In mammals, glial cell proliferation localizes to areas of
severe tissue damage after trauma, ischemia, infection,
autoimmune response, or fast degenerative disease
[5,6,60]. In these cases, proliferative gliosis can contribute
to the formation of scars, which are hypothesized to
impair neuronal function, block axonal regeneration, and
interfere with tissue grafts and integration of transplanted
cells [17,18]. The contribution of glial proliferation to
scar formation was confirmed when proliferating astro-
cytes were genetically ablated after traumatic brain and
spinal cord injury resulting in decreased scar formation.
However, there was also impaired functional recovery
that correlated with enhanced spread and persistence of
inflammatory cells, failure to repair the blood-brain bar-
rier, enhanced tissue damage, neuronal loss, and demyeli-
nation [5,6,60]. The negative outcomes from ablating
proliferative astrocytes argue for the need to define the
individual components of reactive gliosis that are detri-
mental or beneficial to neuronal function and survival. In
our study, inducible Müller glial proliferation, intermedi-
ate filament upregulation and migration did not result in
scar formation, glial dysfunction or neuronal deficits. The
benign impact of inducible proliferative reactive gliosis in
our model might be explained by the relatively low level
of proliferation, but a more likely explanation is the
absence of other changes associated with reactivity such
as hypertrophy, decreased potassium clearance, and loss
of homeostatic and metabolic enzymes [4,11,21,41]. Con-
sequently, the extent to which neuronal cell stress,
microglial reactivity, inflammatory response, blood bar-
rier damage, or neuronal cell death contribute to the
transition from supportive glia to detrimental glia needs
to be determined (Figure 6B).
Conclusions
Reactive gliosis is a ubiquitous but poorly understood
hallmark of CNS and retinal pathologies. Despite the
extensive characterization and manipulation of reactive
gliosis, several questions remain unresolved. What regu-
lates reactive gliosis? Is the response binary or graded?
Is the response detrimental or beneficial to neuronal
function and survival? Our inducible model of p27
inactivation exhibited three indices of glial reactivity–
proliferation, intermediate filament upregulation, and
migratory-like behavior–and allowed us to evaluate their
intrinsic impact on retinal neuron function and survival
(Figure 6A). Our metabolic, electrophysiological, and
visual behavior data argue that proliferative reactive
gliosis is compatible with neuronal metabolism and
function, and that the final detrimental outcome of glial
plasticity during degeneration or injury is determined by
additional factors (Figure 6B). In combination with
genetic, pharmacological or disease model approaches,
the inducible model of proliferative reactive gliosis
based on conditional p27 inactivation will be a powerful
tool to dissect the factors that induce glial dysfunction
or neurogenesis.
Methods
Animals
p27LoxP mice (coisogenic to 129S4) were bred to
CAGG::CreER™ mice (Jax Stock #4453) and back-
crossed 10 generations to 129S4 to generate a tamoxifen
inducible p27 knockout mutation (p27
L/L;CreER™)
[35,36]. The promoter driving Cre-ER™ expression is a
chimeric promoter of the cytomegalovirus immediate-
early enhancer and chicken beta-actin promoter/enhan-
cer (CAGG) known to drive a widespread expression
[36]. Genotyping was performed by PCR as previously
described [35,36]. Tamoxifen-treated controls are listed
in Figure 1C. This research protocol was approved by
the Institutional Animal Care and Use Committee of
the University of Utah, and the Fred Hutchinson Cancer
Research Center, and conforms to the standards in The
Association for Research in Vision and Ophthalmology
(ARVO) statement for the Use of Animals in Ophthal-
mic and Vision Research.
Tamoxifen treatment
Tamoxifen (Sigma) was dissolved in peanut oil (Sigma)
to a concentration of 5 mg·ml
-1.5 0μg of Tamoxifen per
gram of body weight (gbw) was administered to 2-
month-old mice by single daily intraperitoneal injections
for 5 consecutive days. All experimental and control
(referred to as tamoxifen control) mice were exposed to
the identical tamoxifen treatment regimen.
BrdU administration
BrdU (Sigma) was dissolved in 0.1 M phosphate buf-
fered saline, pH 7.4., to a concentration of 10 mg·ml
-1.
100 μg BrdU per gbw was administered by single daily
intraperitoneal injections for 3 consecutive days.
Immunohistology
Tissue samples were prepared, processed and analyzed
as described previously [61]. Table in Additional file 5
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Page 8 of 11lists the antibodies used for this study. Sections were
collected at the level of the optic nerve to make more
direct comparisons between experimental and tamoxi-
fen-control retinas (Additional file 1). Averages from
biological replicates were pooled together to determine
the total average and standard deviation. P-values were
determined with unpaired Student’s t tests.
Computational molecular phenotyping (CMP)
Tissues were fixed as previously described for electron
microscopy (omitting osmium) and serially sectioned at
200 nm onto 12-well HTC Cel-Line slides (Erie Scienti-
fic) ([12,21,42,62], http://prometheus.med.utah.edu/
~marclab/protocols.html). Additional file 5 lists the anti-
bodies compatible with CMP. IgG binding was visua-
lized with silver-intensification of 1.4 nm gold granules
coupled to species-specific secondary IgGs (Nanoprobes,
Yaphank, NY), captured as 8-bit high-resolution (221
nm/pixel) images, mosaicked into large arrays and regis-
tered using IR-tweak software http://www.sci.utah.edu/
~koshevoy/research/. CMP classification (K-means clus-
tering and histogram analysis) was performed as pre-
viously described [42,62]. Monochrome images are
density mapped and rgb images are intensity mapped
(see [42]). All images were prepared in Adobe Photo-
shop
® CS3 (Adobe Systems Inc., San Jose CA).
Mouse electroretinogram (ERG)
Full-field corneal ERGs were recorded with the universal
testing and electrophysiological system UTAS E-3000
(LKC Technologies, Inc., Gaithersburg, MD). Dark adap-
tated mice were anesthetized by intraperitoneal injection
with ketamine (100 mg/kg) and xylazine (10 mg/kg).
Before recording, pupils were dilated with 2.5% pheny-
lephrine (Akorn, Inc., Decatur, IL). Light flash intensities
for scotopic ERGs ranged from -3.7 to 2.8 log cd·m
-2.
Light flash intensities for photopic ERGs ranged from
-0.8 to 2.9 log cd·m
-2 under rod saturating background
l i g h to f1 . 4 8l o gc d · m
-2. Six or fewer flashes were aver-
aged for each intensity level with increasing flash inter-
vals as increasing intensity. Scotopic and photopic ERG
responses of p27
L-/L- mice and age-matched tamoxifen
control mice were analyzed with two-way ANOVA.
Visual acuity test
Optomotor tracking response to moving gratings was
measured using a virtual optomotor system (Opto-
Motry; CerebralMechanics, Lethbridge, Alberta, Canada)
as previously described [47]. The virtual cylinder was
rotated at a constant speed (12°/s). On each trial an
experimenter judged whether the mouse made tracking
movements with its head and neck to follow the drifting
grating. The spatial frequency threshold, the point at
which animals no longer tracked, was obtained by
incrementally increasing the spatial frequency of the
grating at 100% contrast. Thresholds through each eye
were measured separately by reversing the rotation of
the cylinder [47].
Additional material
Additional file 1: p27 inactivation at the periphery and
intermediate filament expression in p27
L-/L- retina.( A-H) Fluoresence
microscopy of retinas from tamoxifen control and p27
L-/L- mice. Time
after inactivation is specified for each panel. (C) Inactivation efficiency
was measured by comparing the number of p27
+ cells colocalizing with
the glial nuclear marker SOX9. Data are expressed as the mean ± SD. (D)
Mosaic of 20× magnification tiles illustrates the location of the central
and peripheral retinal portions, and the optic nerve (ON). Abbreviations:
p27, cyclin-dependent kinase inhibitor CDKN1B; GFAP, glial fibrillary acidic
protein; and SLC1A3, solute carrier family 1, member 3 (also known as
GLAST).
Additional file 2: Upregulation of proliferative markers in Müller
glia exclusive to p27
L-/L- retina.( A-G) Fluoresence microscopy of retinas
from tamoxifen control and p27
L-/L- mice. Time after inactivation is
specified for each panel. Abbreviations: ONL, outer nuclear layer; INL,
inner nuclear layer; RGC, retinal ganglion cell layer; GLUL, glutamine
synthetase; pHH3, phospho-histone H3; PCNA, proliferating cell nuclear
antigen. SOX9, SRY-box containing gene 9; MCM6, minichromosome
maintenance complex component 6; and DAPI, 4’, 6-diamidino-2-
phenylindole.
Additional file 3: Ultrathin immunohistology of p27
L-/L- retina.( A-D)
Immunohistology and analyses based off epon-embedded, ultrathin
sections (200 nm) and silver intensification. (A and B) Radial sections
probed against GLUL. Somas and stalks were numbered in green and
red, respectively. (C) Quantitation of GLUL
+ somas and stalks in oblique
sections. (D) Potential model of morphological changes in dividing
Müller glia and daughter cell. (E) Radial sections probed against GABA.
Abbreviations: ONL, outer nuclear layer; INL, inner nuclear layer; RGC,
retinal ganglion cell layer; GLUL, glutamine synthetase; OPL, outer plexus
layer; BCL, Bipolar cell layer; MCL, Müller cell layer; ACL, amacrine cell
layer; IPL, inner plexus layer; and GABA, g-Aminobutyric acid.
Additional file 4: Immunohistology in p27
L-/L- retina and distal optic
nerve.( A-F) Fluoresence microscopy of retinas (A-D) or distal optic nerve
(E, F) from tamoxifen control and p27
L-/L- mice. Time after inactivation is
specified for each panel. CD44 labels the Müller glia microvilli at the
outer limiting membrane. Abbreviations: KIR4.1, potassium channel,
inward rectifier 4.1.
Additional file 5: Immunoreagents and their compatibility with
computational metabolic profiling (CMP) or immunocytochemistry
(ICC). Table listing immunoreagents.
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